DDDR-02. PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide
Shumpei Onishi(Hiroshima University), Yeshavanth Banasavadi‐Siddegowda(Neurological Surgery), Desmond Brown(Princeton University), Kimberly Rivera-Caraballo(The University of Texas Health Science Center), Kory Johnson(National Institute of Neurological Disorders and Stroke), Sara A. Murphy(The University of Texas Health Science Center), Sridharan Jayamohan(The University of Texas at San Antonio Health Science Center), Sarah Rivas(National Institutes of Health), Stuart Walbridge(National Institutes of Health), Balveen Kaur(Augusta University), Yoshihiro Otani(Okayama University), Ashish H. Shah(University of Miami), Abdel Elkahloun(National Institutes of Health), John D. Heiss(National Institutes of Health), Gangadhara R. Sareddy(The University of Texas at San Antonio Health Science Center), Ashis Chowdhury(The University of Texas Health Science Center at Houston), Dragan Maric(National Institute of Neurological Disorders and Stroke), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Bayu Sisay(National Institutes of Health), Tae Jin Lee(Augusta University), Sangamesh G. Kumbar(University of Connecticut), Ji Young Yoo(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks
|Nature Medicine|2020|768
Microvascular Injury in the Brains of Patients with Covid-19
|New England Journal of Medicine|2020|603
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540
Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast
|Proceedings of the National Academy of Sciences|2010|433